Advertisement

Hot Topics in TAVI: Paravalvular Leak, Thrombosis, PM Implantation, Stroke, Durability

  • Caterina Gandolfo
  • Amerigo Stabile
Chapter

Abstract

Transcatheter aortic valve implantation (TAVI) is a rapidly evolving technique providing robust treatment of severe aortic valve stenosis, at least in high and intermediate risk patient cohorts [1]. However, different important limitations, having a potential impact on patient outcome, still need to be resolved. Indeed, with several first-generation balloon-expandable or self-expanding TAVI prostheses, residual paravalvular aortic regurgitation (PVL) after TAVI has been identified as a significant independent major predictor of acute and long-term mortality. Moreover, conduction disorders requiring pacemaker implantation and also concerns about early (leaflet thrombosis/decreased leaflet motion) and late valve durability, need to be resolved before applying TAVI to lower-risk patient cohorts [2].

References

  1. 1.
    Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG, PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Bosmans J, Paelinck B. Transcatheter aortic valve replacement: a further step towards a patient-tailored therapy. EuroIntervention. 2016;12:695–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Abdel-Wahab M, Zahn R, Horack M, Gerckens U, Schuler G, Sievert H, et al. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German Transcatheter Aortic Valve Interventions Registry. Heart. 2011;97:899–906.CrossRefPubMedGoogle Scholar
  4. 4.
    Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry. J Am Coll Cardiol. 2011;58:2130–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Hahn RT, Pibarot P, Stewart WJ, Weissman NJ, Gopalakrishnan D, Keane MG, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: a longitudinal study of echocardiography parameters in cohort a of the PARTNER trial (placement of aortic transcatheter valves). J Am Coll Cardiol. 2013;61:2514–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jerez-Valero M, Urena M, Webb JG, Tamburino C, Munoz-Garcia AJ, Cheema A, et al. Clinical impact of aortic regurgitation after transcatheter aortic valve replacement: insights into the degree and acuteness of presentation. JACC Cardiovasc Interv. 2014;7:1022–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards Sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015;36:449–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Jones B, Tuzcu E, Krishnaswamy A, Popovic Z, Mick S, Roselli E, et al. Prognostic significance of mild AR in predicting mortality after TAVR. J Thorac Cardiovasc Surg. 2016;152:783–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8:340–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Reardon MJ, Popma JJ. Residual aortic regurgitation after transcatheter aortic valve replacement under the echocardiographic microscope. J Thorac Cardiovasc Surg. 2016;152:659–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Herrmann HC, Thourani VH, Kodali SK, Makkar RR, Szeto WY, Anwaruddin S, Desai N, Lim S, Chris Malaisrie S, Kereiakes DJ, Ramee S, Greason KL, Kapadia S, Babaliaros V, Hahn RT, Pibarot P, Weissman NJ, Leipsic J, Whisenant BK, Webb JG, Mack MJ, Leon MB, PARTNER Investigators. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134:130–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Hoffmann R, Herpertz R, Lotfipour S, et al. Impact of a new conduction defect after transcatheter aortic valve implantation on left ventricular function. JACC Cardiovasc Interv. 2012;5:1257–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Tzikas A, van Dalen BM, Van Mieghem NM, et al. Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic-CoreValve and the effect on left ventricular ejection fraction. Am J Cardiol. 2011;107:285–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Franzoni I, Latib A, Maisano F, et al. Comparison of incidence and predictors of left bundle branch block after transcatheter aortic valve implantation using the CoreValve versus the Edwards valve. Am J Cardiol. 2013;112:554–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60:1743–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Binder RK, Rodés-Cabau J, Wood DA, et al. Transcatheter aortic valve replacement with the SAPIEN 3: a new balloon-expandable transcatheter heart valve. J Am Coll Cardiol Intv. 2013;6:293–300.CrossRefGoogle Scholar
  17. 17.
    Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64:2235–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Tarantini G, Mojoli M, Purita P, et al. Unravelling the (arte)fact of increased pacemaker rate with the Edwards SAPIEN 3 valve. EuroIntervention. 2015;11:343–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Murray MI, Geis N, Pleger ST, et al. First experience with the new generation Edwards SAPIEN 3 aortic bioprosthesis: procedural results and short term outcome. J Interv Cardiol. 2015;28:109–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PWJC, Kappetein AP, SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Buellesfeld L, Stortecky S, Heg D, et al. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;60:493–501.CrossRefPubMedGoogle Scholar
  22. 22.
    Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation following transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation. 2013;129:1233–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Chevreul K, Brunn M, Cadier B, et al. Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Arch Cardiovasc Dis. 2013;106:209–19.CrossRefPubMedGoogle Scholar
  24. 24.
    Tops LF, Schalij MJ, Bax JJ. The effects of right ventricular apical pacing on ventricular function and dyssynchrony: implications for therapy. J Am Coll Cardiol. 2009;54:764–76.CrossRefPubMedGoogle Scholar
  25. 25.
    Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valvar complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Interv. 2008;1:74–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Nazif TM, Williams MR, Hahn RT, Kapadia S, Babaliaros V, Rodés-Cabau J, et al. Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience. Eur Heart J. 2013;35:1599–607.CrossRefPubMedGoogle Scholar
  27. 27.
    Moreno R, Dobarro D, Lopez de Sa E, Prieto M, Morales C, Calvo Orbe L, Moreno-Gomez I, Filgueiras D, Sanchez-Recalde A, Galeote G, Jimenez-Valero S, Lopez-Sendon JL. Cause of complete atrioventricular block after percutaneous aortic valve implantation: insights from a necropsy study. Circulation. 2009;120:e29–30.CrossRefPubMedGoogle Scholar
  28. 28.
    Saji M, MuraiT TT, Tabata M, Takanashi S, Takayama M. Autopsy finding of the Sapien XT valve from a patient who died suddenly after transcatheter aortic valve replacement. Cardiovasc Interv Ther. 2013;28:267–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Roten L, Wenaweser P, Delacrétaz E, et al. Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. Am J Cardiol. 2010;106:1473–80.CrossRefPubMedGoogle Scholar
  30. 30.
    Siontis GC, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Patrick Mayr N, Kasel AM, Kastrati A, Schunkert H, Hengstenberg C. Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv. 2016;3:244–54.CrossRefGoogle Scholar
  32. 32.
    Kapadia SR, Leon MB, Makkar RR, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio- Thoracic Surgery (EACTS), Vahanian A, Alfieri O, et al. Guidelines on the management of valvular heart disease (version 2012). Eur J Cardiothorac Surg. 2012;42:S1–44.CrossRefGoogle Scholar
  34. 34.
    Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefPubMedGoogle Scholar
  35. 35.
    Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Mack MJ, Leon MB, Smith CR, et al. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84.CrossRefPubMedGoogle Scholar
  37. 37.
    Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, Smalling R, Lim S, Malaisrie SC, Kapadia S, Szeto WY, Greason KL, Kereiakes D, Ailawadi G, Whisenant BK, Devireddy C, Leipsic J, Hahn RT, Pibarot P, Weissman NJ, Jaber WA, Cohen DJ, Suri R, Tuzcu EM, Svensson LG, Webb JG, Moses JW, Mack MJ, Miller DC, Smith CR, Alu MC, Parvataneni R, D’Agostino RB Jr, Leon MB. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–25.CrossRefPubMedGoogle Scholar
  38. 38.
    Dvir D, Eltchaninoff H, Ye J, Kan A, Durand E, Bizios A, Cheung A, Aziz M, Simonato M, Tron C, Arbel Y, Moss R, Leipsic J, Ofek H, Perlman G, Barbanti M, Seidman MA, Blanke P, Yao R, Boone R, Lauck S, Lichtenstein S, Wood D, Cribier A, Webb J. First look at long-term durability of transcatheter heart valves: assessment of valve function up to 10-years after implantation. EuroPCR, Paris, 2016.Google Scholar
  39. 39.
    Eltchaninoff H. Clinical experiences and echo data from Rouen. Chicago: Presented at TVT; 2016.Google Scholar
  40. 40.
    Webb JG, Dvir D. Ten year follow-up of TAVI from Vancouver. Chicago: Presented at TVT; 2016.Google Scholar
  41. 41.
    Johnston DR, Soltesz EG, Vakil N, et al. Longterm durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac Surg. 2015;99:1239–47.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Søndergaard L. Possible subclinical leaflet thrombosis in bioprostheticaortic valves. N Engl J Med. 2015;373:2015–24.  https://doi.org/10.1056/NEJMoa1509233.CrossRefPubMedGoogle Scholar
  43. 43.
    Holmes DR, Mack MJ. Uncertainty and possible subclinical valve leaflet thrombosis. N Engl J Med. 2015;373:2080–2.  https://doi.org/10.1056/NEJMe1511683.CrossRefPubMedGoogle Scholar
  44. 44.
    De Marchena E, Mesa J, Pomenti S, Marin Y, Kall C, Marincic X, Yahagi K, Ladich E, Kutz R, Aga Y, Ragosta M, Chawla A, Ring ME, Virmani R. Thrombus formation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2015;8:728–39.  https://doi.org/10.1016/j.jcin.2015.03.005.CrossRefPubMedGoogle Scholar
  45. 45.
    Tourmousoglou C, Rao V, Lalos S, Dougenis D. What is the best approach in a patient with a failed aortic bioprosthetic valve: transcatheter aortic valve replacement or redo aortic valve replacement? Interact Cardiovasc Thorac Surg. 2015;20:837–43.  https://doi.org/10.1093/icvts/ivv037.CrossRefPubMedGoogle Scholar
  46. 46.
    Leetmaa T, Hansson NC, Leipsic J, Jensen K, Poulsen SH, Andersen HR, Jensen JM, Webb J, Blanke P, Tang M, Norgaard BL. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv. 2015;8:e001596.  https://doi.org/10.1161/Circinterventions.114.001596.CrossRefPubMedGoogle Scholar
  47. 47.
    Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, Connolly HM. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol. 2015;66:2285–94.  https://doi.org/10.1016/j.jacc.2015.09.022.CrossRefPubMedGoogle Scholar
  48. 48.
    Córdoba-Soriano JG, Puri R, Amat-Santos I, Ribeiro HB, Abdul-Jawad Altisent O, del Trigo M, Paradis JM, Dumont E, Urena M, Rodés-Cabau J. Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Esp Cardiol (Engl Ed). 2015;68:198–204.  https://doi.org/10.1016/j.rec.2014.10.003.CrossRefGoogle Scholar
  49. 49.
    Latib A, Messika-Zeitoun D, Maisano F, Himbert D, Agricola E, Brochet E, Alfieri O, Colombo A, Vahanian A. Reversible Edwards Sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol. 2013;61:787–9.  https://doi.org/10.1016/j.jacc.2012.10.016.CrossRefPubMedGoogle Scholar
  50. 50.
    Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg. 2012;144:108–11.  https://doi.org/10.1016/j.jtcvs.2011.05.032.CrossRefPubMedGoogle Scholar
  51. 51.
    Pislaru SV, Hussain I, Pellikka PA, Maleszewski JJ, Hanna RD, Schaff HV, Connolly HM. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg. 2015;47:725–32.  https://doi.org/10.1093/ejcts/ezu201.CrossRefPubMedGoogle Scholar
  52. 52.
    Nkomo VT, Suri RM, Pislaru SV, Greason KL, Sinak LJ, Holmes DR, Mathew V, Rihal CS. Delayed transcatheter heart valve migration and failure. JACC Cardiovasc Imaging. 2014;7:960–2.  https://doi.org/10.1016/j.jcmg.2014.02.010.CrossRefPubMedGoogle Scholar
  53. 53.
    Latib A, Naganuma T, Abdel-Wahab M, Danenberg H, Cota L, Barbanti M, Baumgartner H, Finkelstein A, Legrand V, de Lezo JS, Kefer J, Messika-Zeitoun D, Richardt G, Stabile E, Kaleschke G, Vahanian A, Laborde JC, Leon MB, Webb JG, Panoulas VF, Maisano F, Alfieri O, Colombo A. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015;8:e001779.  https://doi.org/10.1161/CIRCINTERVENTIONS.114.001779.CrossRefPubMedGoogle Scholar
  54. 54.
    Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC, Nombela-Franco L, Cheema AN, Gutierrez E, Serra V, Kefer J, Amat-Santos IJ, Benitez LM, Mewa J, Jiménez-Quevedo P, Alnasser S, Garcia Del Blanco B, Dager A, Abdul-Jawad Altisent O, Puri R, Campelo-Parada F, Dahou A, Paradis JM, Dumont E, Pibarot P, Rodés-Cabau J. Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol. 2016;67:644–55.  https://doi.org/10.1016/j.jacc.2015.10.097.CrossRefPubMedGoogle Scholar
  55. 55.
    Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, Szeto WY, Dewey TM, Guyton RA, Bavaria JE, Babaliaros V, Gammie JS, Svensson L, Williams M, Badhwar V, Mack MJ. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg. 2015;99:55–61.  https://doi.org/10.1016/j.athoracsur.2014.06.050.CrossRefPubMedGoogle Scholar
  56. 56.
    Jander N, Sommer H, Pingpoh C, Kienzle RP, Martin G, Zeh W, Pache G, Siepe M, Beyersdorf F, Schumacher M, Neumann FJ, Minners J. The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position. Int J Cardiol. 2015;199:90–5.  https://doi.org/10.1016/j.ijcard.2015.07.022.CrossRefPubMedGoogle Scholar
  57. 57.
    Vemulapalli S, Dai D, Mack MJ, Holmes DR, Grover F, Makkar R, Thourani VH, Douglas PS; STS/ACC TVT Registry. Incidence and outcomes of valve hemodynamic deterioration in transcatheteraortic valve replacement in U.S. clinical practice: a report from the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy Registry. Presented at American College of Cardiology Meeting; April 2–4, 2016; Chicago, IL.Google Scholar
  58. 58.
    Laschinger JC, Wu C, Ibrahim NG, Shuren JE. Reduced leaflet motion in bioprosthetic aortic valves: the FDA perspective. N Engl J Med. 2015;373:1996–8.  https://doi.org/10.1056/NEJMp1512264.CrossRefPubMedGoogle Scholar
  59. 59.
    Giustino G, Sorrentino S, Mehran R, Faggioni M, Dangas G. Cerebral embolic protection during TAVR. A clinical event meta-analysis. J Am Coll Cardiol. 2017;69:463–70.CrossRefGoogle Scholar
  60. 60.
    Piazza N, Kalesan B, van Mieghem N, Head S, Wenaweser P, Carrel TP, Bleiziffer S, de Jaegere PP, Gahl B, Anderson RH, Kappetein AP, Lange R, Serruys PW, Windecker S, Jüni P. A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients. JACC Cardiovasc Interv. 2013;6:443–51.CrossRefPubMedGoogle Scholar
  61. 61.
    Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pilgrim T, Gloekler S, O’Sullivan CJ, Meier B, Jüni P, Carrel T, Windecker S. Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J. 2013;34:1894–905.CrossRefPubMedGoogle Scholar
  62. 62.
    Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrøm T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Søndergaard L. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT)IRCSS UPMC ITALYPalermoItaly
  2. 2.Maria Eleonora HospitalPalermoItaly

Personalised recommendations